Cobenfy for Schizophrenia

SP
Overseen ByShannon Peleg
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: New York State Psychiatric Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. \[18F\]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission.

The overall objective of the current study is to measure Cobenfy's ability to engage its putative target (DA transmission/synthesis capacity in the striatum and midbrain as measured by \[18F\]DOPA Kicer (\[18F\]DOPA relative uptake rate)).

Who Is on the Research Team?

JT

Joshua T Kantrowitz, MD

Principal Investigator

New York State Psychiatric Institute

RG

Ragy Girgis, MD

Principal Investigator

New York State Psychiatric Institute

Are You a Good Fit for This Trial?

Inclusion Criteria

I am between 18 and 50 years old.
5. PANSS total score \> 80 and \< 120
I understand the study and can give my consent to join.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to one of three doses of Cobenfy for 5 weeks, with PET scans before and after treatment to examine effects on dopamine transmission

5 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Cobenfy

How Is the Trial Designed?

3

Treatment groups

Experimental Treatment

Group I: Xanomeline 50 mg and trospium chloride 20mg (KarXT)Experimental Treatment1 Intervention
Group II: Xanomeline 125 mg and trospium chloride 30mg (KarXT)Experimental Treatment1 Intervention
Group III: Xanomeline 100 mg and trospium chloride 20mg (KarXT)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

New York State Psychiatric Institute

Lead Sponsor

Trials
481
Recruited
154,000+

Bristol-Myers Squibb

Industry Sponsor

Trials
2,731
Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia
Christopher Boerner profile image

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt profile image

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania